Non-Hodgkin Lymphoma

Table of Contents

  1. Overview
  2. Epidemiology and Risk Factors
  3. Classification: B-cell vs. T-cell Lymphomas
  4. Diffuse Large B-Cell Lymphoma (DLBCL)
  5. Follicular Lymphoma
  6. Other Indolent and Aggressive Subtypes
  7. Staging and Diagnosis
  8. Treatment Overview
  9. Novel Therapies: CAR-T, Bispecifics
  10. References & Research
  11. Research Papers
  12. Connections
  13. Featured Videos

1. Overview

Non-Hodgkin lymphoma (NHL) is not a single disease but a large, biologically heterogeneous family of more than 60 distinct lymphoid malignancies arising from B cells, T cells, or NK cells at various stages of differentiation. With approximately 80,000 new cases per year in the United States, NHL is the fifth most common cancer overall and the most common hematologic malignancy. Its annual incidence has roughly doubled since the 1970s, partly from genuine increases (improved surveillance, HIV epidemic, increased immunosuppression) and partly from reclassification of previously unrecognized entities.

Understanding NHL requires grasping two fundamental axes: the cell of origin (B-cell vs. T-cell/NK-cell) and the clinical tempo (indolent, meaning slow-growing and incurable but manageable for years, vs. aggressive, meaning rapidly growing but potentially curable). The most common aggressive NHL is diffuse large B-cell lymphoma (DLBCL), accounting for 30% of all NHL. The most common indolent NHL is follicular lymphoma (FL), accounting for 20–25% of all NHL. These two subtypes illustrate the two very different challenges in NHL management: DLBCL requires immediate treatment with curative intent; FL requires careful timing of treatment to avoid over-treating a disease that is genuinely manageable without therapy in many early cases.

The last decade has seen a transformation in NHL treatment driven by four major developments: rituximab (anti-CD20 antibody) incorporated into virtually every B-cell NHL regimen; targeted small-molecule inhibitors (ibrutinib, venetoclax) for specific subtypes; CAR-T cell therapy for relapsed/refractory aggressive B-cell lymphomas; and bispecific antibodies that redirect T cells to kill CD20-positive lymphoma cells. The era of purely cytotoxic chemotherapy is giving way to rational biological targeting.

2. Epidemiology and Risk Factors

NHL incidence increases with age and is slightly more common in men than women (ratio approximately 1.3:1). The median age at diagnosis is about 60, though specific subtypes like Burkitt lymphoma and pediatric lymphoblastic lymphoma disproportionately affect younger patients.

Established risk factors vary by subtype but include:

3. Classification: B-Cell vs. T-Cell Lymphomas

The WHO classification of lymphoid tumors organizes NHL by cell of origin and stage of differentiation:

4. Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is the most common aggressive lymphoma and the most common NHL overall in adults. It is potentially curable but requires prompt treatment. The molecular heterogeneity within DLBCL has become one of the most intensively studied topics in lymphoma biology:

Cell of origin: GCB vs. ABC

Gene expression profiling and immunohistochemistry (IHC) via the Hans algorithm divide DLBCL into:

First-line treatment: R-CHOP and Pola-R-CHP

R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) has been the standard first-line treatment for DLBCL for over two decades. It achieves cure in approximately 60–65% of patients with DLBCL. Six cycles every 21 days is the most widely used schedule.

The POLARIX trial (PMID 34891063) established Pola-R-CHP (polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, substituted for vincristine in R-CHOP) as a new option for previously untreated intermediate-to-high risk DLBCL (IPI ≥2). Pola-R-CHP improved progression-free survival (HR 0.73) compared with R-CHOP in this study, with a manageable safety profile. It is now approved and used in the front-line setting for intermediate/high-risk DLBCL, though its benefit appears concentrated in the non-GCB (ABC) subtype in subgroup analyses.

Prognostic scoring

The International Prognostic Index (IPI) assigns 1 point each for age >60, elevated LDH, ECOG performance status ≥2, Ann Arbor stage III–IV, and more than one extranodal site. Low (0–1), low-intermediate (2), high-intermediate (3), and high (4–5) risk groups predict 5-year overall survival ranging from ~90% to ~50% in the R-CHOP era.

5. Follicular Lymphoma

Follicular lymphoma (FL) is the prototypical indolent B-cell lymphoma and the most common low-grade NHL. It is characterized by a t(14;18) translocation in >85% of cases, juxtaposing the BCL2 anti-apoptotic gene to the immunoglobulin heavy-chain promoter, leading to constitutive BCL2 overexpression and failure of normal germinal center B-cell apoptosis.

Grading and transformation

FL is graded histologically by the number of centroblasts per high-power field: grade 1–3a (predominantly centrocytes with few to many centroblasts) are indolent; grade 3b (confluent sheets of centroblasts) is treated like DLBCL. A major long-term concern is histologic transformation to DLBCL, which occurs at approximately 2–3% per year, accumulating to 15–30% at 10 years. Transformed FL is associated with aggressive clinical behavior and poor prognosis with standard therapy.

Watch-and-wait approach

Asymptomatic patients with low-bulk FL (small-volume disease, normal LDH, no B symptoms, no organ compromise — the so-called "GELF criteria" negative) can be safely managed with active surveillance without immediate treatment. The RESORT trial (PMID 23012332) demonstrated that rituximab maintenance did not improve overall survival over observation after initial rituximab induction in low-tumor-burden FL, supporting the watch-and-wait approach in appropriate patients. Many patients remain on observation for years or decades.

Treatment when indicated

When treatment is required (symptomatic disease, high-bulk disease, cytopenias, or organ compromise), the backbone is chemoimmunotherapy:

6. Other Indolent and Aggressive Subtypes

Marginal zone lymphomas (MZL)

Three types: extranodal MALT lymphoma (mucosa-associated lymphoid tissue, most common site is stomach, driven by H. pylori; eradication alone achieves remission in H. pylori-positive gastric MALT), nodal MZL, and splenic MZL. MALT lymphomas are among the most manageable malignancies when treated appropriately for their site and etiology.

Mantle cell lymphoma (MCL)

MCL is classically considered aggressive (MIPI index stratifies risk), driven by t(11;14) with cyclin D1 overexpression. Treatment in younger fit patients involves R-CHOP or R-Hyper-CVAD alternating with R-methotrexate/cytarabine, followed by autologous SCT consolidation. The BTK inhibitor ibrutinib and its next-generation successors (acalabrutinib, zanubrutinib) have transformed relapsed MCL management. A blastoid variant is particularly aggressive with poor outcomes.

Burkitt lymphoma

The most rapidly proliferating human cancer (Ki-67 approaching 100%), driven by MYC translocation. Requires immediate intensive treatment (R-CODOX-M/IVAC or dose-adjusted EPOCH-R). Highly curable in young patients and children; less favorable in older adults. Tumor lysis syndrome risk is extreme and requires aggressive prophylaxis.

Peripheral T-cell lymphomas (PTCL)

Heterogeneous group with generally poor outcomes with standard CHOP-based therapy. Median OS for PTCL-NOS is approximately 3–5 years. Exceptions: ALK-positive ALCL has excellent prognosis (5-year OS ~80%) with CHOP + brentuximab vedotin (A+CHP, ECHELON-2 trial). Consolidation with autologous SCT in first remission is considered in fit patients with most PTCL subtypes.

7. Staging and Diagnosis

Diagnosis requires adequate tissue biopsy — excisional or core biopsy with immunohistochemistry, flow cytometry, and molecular studies (FISH for translocations, gene expression profiling). Fine needle aspiration alone is insufficient for most NHL diagnoses due to architectural effacement that cannot be assessed on cytology.

Staging workup:

8. Treatment Overview

Treatment strategy is entirely determined by NHL subtype, stage, and patient fitness. The broad principles:

Radiation therapy plays a role in localized NHL (stage I–II) as a component of combined modality therapy or as palliative treatment for bulky symptomatic disease.

CNS prophylaxis (intrathecal or high-dose systemic methotrexate) is administered to high-risk DLBCL patients to reduce the risk of CNS relapse, which carries a dismal prognosis.

9. Novel Therapies: CAR-T and Bispecific Antibodies

The last five years have produced a revolution in the treatment of relapsed/refractory B-cell NHL, with several novel immunotherapy approaches achieving durable remissions in patients for whom outcomes were previously dismal.

CAR-T cell therapy

Chimeric antigen receptor T-cell (CAR-T) therapy engineers the patient's own T cells to express a receptor targeting CD19 (expressed on all B cells). Three products are FDA-approved for relapsed/refractory DLBCL:

CAR-T therapy has also been moved to the second-line setting in eligible patients with early relapse (<12 months) or refractory disease, where ZUMA-7 (axi-cel) and TRANSFORM (liso-cel) trials showed superiority over standard salvage + ASCT.

Bispecific antibodies

Bispecific T-cell-engaging antibodies simultaneously bind CD20 on lymphoma cells and CD3 on T cells, redirecting polyclonal endogenous T cells to kill tumor cells without requiring T-cell engineering. This "off-the-shelf" approach avoids the logistical complexity and manufacturing time of CAR-T:

Bispecific antibodies are being investigated in combination with other agents and in earlier lines of therapy, with the goal of further improving outcomes in aggressive NHL.

10. References & Research

Key Research Papers

  1. Tilly et al., 2022 (POLARIX) — PMID: 34891063 — Pola-R-CHP vs. R-CHOP for untreated DLBCL: improved PFS with polatuzumab vedotin in IPI ≥2 patients.
  2. Marcus et al., 2017 (GALLIUM) — PMID: 28291524 — Obinutuzumab + chemotherapy vs. rituximab + chemotherapy for FL: obinutuzumab improved PFS.
  3. Kahl et al., 2014 (RESORT) — PMID: 23012332 — Rituximab maintenance vs. re-treatment at relapse for low-tumor-burden FL: no OS advantage for maintenance.
  4. Neelapu et al., 2017 (ZUMA-1) — PMID: 28985560 — Axi-cel CAR-T for R/R DLBCL: 72% ORR, 54% CR; landmark CAR-T pivotal trial.
  5. Schuster et al., 2019 (JULIET) — PMID: 30501965 — Tisa-cel for R/R DLBCL: 52% ORR; global CAR-T multicenter trial.
  6. Abramson et al., 2020 (TRANSCEND) — PMID: 32868245 — Liso-cel for R/R large B-cell lymphoma: 73% ORR with defined lower-toxicity profile.
  7. Topp et al., 2023 (EPCORE NHL-1) — PMID: 37392427 — Epcoritamab for R/R DLBCL: 61% ORR in heavily pretreated patients; off-the-shelf bispecific antibody.
  8. Younes et al., 2019 (ECHELON-2) — PMID: 25979958 — A+CHP vs. CHOP for CD30-positive PTCL: brentuximab vedotin improved PFS and OS.
  9. Rosenwald et al., 2002 — PMID: 27264919 — GCB vs. ABC molecular subtyping of DLBCL by gene expression profiling; prognostic significance of cell-of-origin.
  10. Hans et al., 2004 — PMID: 20660802 — Validation of IHC-based Hans algorithm (CD10/BCL6/MUM1) as surrogate for GEP-based COO classification in DLBCL.
  11. Friedberg, 2011 — PMID: 22898598 — Relapsed/refractory DLBCL: salvage regimens and ASCT outcomes; basis for standard second-line approach.
  12. Coiffier et al., 2010 — PMID: 16493005 — R-CHOP 10-year follow-up for DLBCL: 60–65% long-term cure rate established; landmark rituximab era trial.

Research Papers

The links below run live searches on PubMed, the U.S. National Library of Medicine's database of biomedical literature.

  1. DLBCL R-CHOP treatment outcomes
  2. CAR-T cell therapy B-cell lymphoma
  3. Follicular lymphoma watch and wait
  4. NHL bispecific antibody epcoritamab
  5. Mantle cell lymphoma ibrutinib
  6. DLBCL GCB ABC cell of origin prognosis
  7. Follicular lymphoma transformation to DLBCL
  8. Peripheral T-cell lymphoma treatment
  9. MALT lymphoma H. pylori treatment
  10. Burkitt lymphoma treatment outcomes
  11. NHL PET-CT staging response assessment
  12. Double-hit lymphoma MYC BCL2

Connections

Back to Table of Contents